Bostel Tilman, Förster Robert, Schlampp Ingmar, Sprave Tania, Bruckner Thomas, Nicolay Nils Henrik, Welte Stefan Ezechiel, Debus Jürgen, Rief Harald
Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Radiat Oncol. 2017 Jul 11;12(1):115. doi: 10.1186/s13014-017-0852-6.
This retrospective analysis aimed to analyse the stability of spinal bone metastases in colorectal cancer (CRC) patients following radiotherapy (RT) by use of a validated score and to assess prognostic factors for stability and survival.
Ninety-four patients with osteolytic spinal bone metastases from CRC were treated at the Department of Radiation Oncology at the University Hospital Heidelberg between 2000 and 2014. The stability of each affected vertebral body was assessed according to the validated Taneichi bone stability score on the basis of the treatment planning CT scan prior to RT and also based on the follow-up CT examinations at 3 and 6 months after RT. Additionally, bone survival rates (time between first day of RT and death from any cause) as well as prognostic factors for bone survival were evaluated for all study patients.
Before RT, 59 patients (63%) were rated unstable according to the Taneichi score. Pathological fractures within the irradiated region were diagnosed in 43 patients (46%) prior to RT. New fractures or progression of previously collapsed vertebrae were diagnosed in 4 patients (4%) after irradiation. Significant re-calcification and stabilization of former unstable bone metastases was only observed in 3/59 patients (3%) and 5/59 patients (9%). The median bone survival was 4.2 months (range 0.5-67.3 months) and 6 months after RT 61% of the patients were dead. Karnofsky performance score (KPS) (< 70% vs. ≥ 70%), chemotherapy and bisphosphonate therapy were predictive prognostic factors for bone survival.
Our study population is characterized by poor bone survival and low re-calcification rates of unstable spinal bone lesions 3 and 6 months after RT. To avoid unnecessary hospitalisation and improve remaining QoL, short fractionated treatment schedules of RT may be prefered in this highly palliative situation, particularly for patients with a KPS < 70%.
本回顾性分析旨在通过使用经过验证的评分系统分析结直肠癌(CRC)患者放疗(RT)后脊柱骨转移的稳定性,并评估稳定性和生存的预后因素。
2000年至2014年间,海德堡大学医院放射肿瘤学系对94例患有溶骨性脊柱骨转移的CRC患者进行了治疗。根据经过验证的谷内骨稳定性评分,基于放疗前的治疗计划CT扫描以及放疗后3个月和6个月的随访CT检查,评估每个受影响椎体的稳定性。此外,还评估了所有研究患者的骨生存率(从放疗第一天到因任何原因死亡的时间)以及骨生存的预后因素。
放疗前,根据谷内评分,59例患者(63%)被评为不稳定。放疗前,43例患者(46%)在照射区域内被诊断为病理性骨折。放疗后,4例患者(4%)被诊断为新的骨折或先前塌陷椎体的进展。仅在3/59例患者(3%)和5/59例患者(9%)中观察到先前不稳定骨转移的显著重新钙化和稳定。中位骨生存时间为4.2个月(范围0.5 - 67.3个月),放疗后6个月61%的患者死亡。卡诺夫斯基性能评分(KPS)(<70%与≥70%)、化疗和双膦酸盐治疗是骨生存的预测性预后因素。
我们的研究人群的特点是骨生存率低,放疗后3个月和6个月不稳定脊柱骨病变的重新钙化率低。为避免不必要的住院并改善剩余的生活质量,在这种高度姑息的情况下,尤其是对于KPS < 70%的患者,短程分割放疗方案可能更受青睐。